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BACKGROUND: Patients with heterozygous familial hypercholesterolemia 
(FH) and coronary heart disease have high mortality rates. However, in an 
era of high-dose statin prescription after acute coronary syndrome (ACS), 
the risk of recurrent coronary and cardiovascular events associated with FH 
might be mitigated. We compared coronary event rates between patients 
with and without FH after ACS.
METHODS: We studied 4534 patients with ACS enrolled in a multicenter, 
prospective cohort study in Switzerland between 2009 and 2013 who were 
individually screened for FH on the basis of clinical criteria according to 3 
definitions: the American Heart Association definition, the Simon Broome 
definition, and the Dutch Lipid Clinic definition. We used Cox proportional models 
to assess the 1-year risk of first recurrent coronary events defined as coronary 
death or myocardial infarction and adjusted for age, sex, body mass index, 
smoking, hypertension, diabetes mellitus, existing cardiovascular disease, high-
dose statin at discharge, attendance at cardiac rehabilitation, and the GRACE 
(Global Registry of Acute Coronary Events) risk score for severity of ACS.
RESULTS: At the 1-year follow-up, 153 patients (3.4%) had died, including 104 
(2.3%) of fatal myocardial infarction. A further 113 patients (2.5%) experienced 
nonfatal myocardial infarction. The prevalence of FH was 2.5% with the 
American Heart Association definition, 5.5% with the Simon Broome definition, 
and 1.6% with the Dutch Lipid Clinic definition. Compared with patients without 
FH, the risk of coronary event recurrence after ACS was similar in patients with 
FH in unadjusted analyses, although patients with FH were >10 years younger. 
However, after multivariable adjustment including age, the risk was greater 
in patients with FH than without, with an adjusted hazard ratio of 2.46 (95% 
confidence interval, 1.07–5.65; P=0.034) for the American Heart Association 
definition, 2.73 (95% confidence interval, 1.46–5.11; P=0.002) for the Simon 
Broome definition, and 3.53 (95% confidence interval, 1.26–9.94; P=0.017) 
for the Dutch Lipid Clinic definition. Depending on which clinical definition of FH 
was used, between 94.5% and 99.1% of patients with FH were discharged 
on statins and between 74.0% and 82.3% on high-dose statins.
CONCLUSIONS: Patients with FH and ACS have a >2-fold adjusted risk of 
coronary event recurrence within the first year after discharge than patients 
without FH despite the widespread use of high-intensity statins.
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heterozygous familial hypercholesterolemia (FH) is a common monogenic disorder associated with elevated low-density lipoprotein (LDL) cholesterol 
levels and premature coronary heart disease (CHD). 
Several definitions of FH have been proposed by expert 
groups that use LDL cholesterol and/or personal or 
family history of premature CHD.1–3 Unfortunately, FH re-
mains largely underdiagnosed in the general population, 
and many patients with FH are diagnosed only at the 
time of their first coronary event.4 In Europe, up to 8% of 
adults hospitalized for acute coronary syndromes (ACS) 
have been shown to have clinical criteria compatible with 
FH,5,6 which is >10 times greater than the prevalence 
of FH in the general population. However, even if FH is 
frequent among patients with premature CHD, there is 
still no established screening strategy to decrease the 
number of missed diagnoses.7 Moreover, prognosis 
data are lacking in patients with FH in the setting of ACS, 
particularly in the era of widespread statin use.
The benefit of statins versus placebo on cardiovascular 
outcomes for patients with FH has never been established 
in a randomized, controlled trial.8,9 Furthermore, very few 
data document the likelihood of cardiovascular event re-
currence in patients with ACS with FH compared with those 
with no FH.10 Thus, it is unknown whether further identifi-
cation of FH is required for a more targeted secondary 
prevention approach, despite the widespread adoption of 
high-dose statins after ACS. Accordingly, we investigated 
whether a diagnosis of FH among ACS patients was as-
sociated with a greater recurrence risk of coronary events 
compared with ACS patients without FH independently of 
cardiovascular risk factors and severity of ACS.
MethODs
study Population
The SPUM-ACS study (Special Program University Medicine-
Acute Coronary Syndromes) is a prospective cohort study 
of consecutive patients hospitalized with ACS in Switzerland. 
The study was designed to identify new determinants and con-
sequences of CHD. Details of the methods of the SPUM-ACS 
study have been reported previously.11–13 Briefly, all patients 
hospitalized with ACS in 4 university hospitals in Switzerland 
were invited to participate with no exclusion criteria except 
severe physical disability, inability to give consent owing to 
dementia, and life expectancy of <1 year for noncardiac rea-
sons. Inclusion criteria were age ≥18 years, a main diagnosis 
of ST-elevation–elevation myocardial infarction for patients 
presenting after pain onset, non–ST-segment–elevation myo-
cardial infarction, or unstable angina. Overall, clinical follow-
up information at 1 year was available for 5045 of patients 
included in the SPUM-ACS cohort study between September 
2009 and September 2013. Baseline lipid measurements were 
missing for 453 patients (9%), and an additional 58 patients 
(1.3%) had missing family history information. Thus, the final 
population for this analysis included 4534 patients.
Diagnosis of Fh
The diagnosis of FH was based on 3 different definitions rec-
ommended by international guidelines (Tables I–III in the online-
only Data Supplement). The latest statement of the American 
Heart Association combined LDL cholesterol >190 mg/dL 
and a family history of a first-degree relative with premature 
CHD.1 The Simon Broome definition recommended by National 
Institute for Health and Care Excellence guidelines used total 
cholesterol >290 mg/dL or LDL cholesterol >190 mg/dL and 
a personal or family history of premature coronary disease.3 
Finally, the Dutch Lipid Clinic definition also used LDL choles-
terol levels and a personal or family history of premature CHD. 
A possible FH was defined by a score of 3 to 5, and a prob-
able/definite FH by a score of ≥6.2 As done previously,5 cuta-
neous signs and genetic tests of FH were counted as zero in 
all definitions because this type of information was missing for 
too many patients. For the Simon Broome definition in which 
such items are included, only a possible diagnosis of FH could 
be provided.
clinical Outcomes
The occurrence of clinical events during the first year after hos-
pitalization for ACS was obtained by monitoring participants 
by telephone at 30 days after discharge and again in a clinical 
face-to-face visit at 1 year after ACS. Coronary events were 
defined as the occurrence of fatal or nonfatal myocardial infarc-
tion. Cardiovascular events were defined as the occurrence 
of myocardial infarction, ischemic stroke, transient ischemic 
clinical Perspective
What is new?
•	With the use of clinical criteria proposed by several 
expert groups, the prevalence of familial hypercho-
lesterolemia (FH) reached 5% in a large cohort of 
patients hospitalized with acute coronary syndrome 
(ACS) in Switzerland, which may be 10 times greater 
than in the general population.
•	Although nearly all patients with FH were discharged 
on statins, mostly high-dose statins, only a few 
achieved the recommended low-density lipoprotein 
cholesterol levels 1 year after ACS.
•	Patients with FH had a 2-fold increased risk of coro-
nary event recurrence within the first year after ACS 
compared with same-age patients without FH.
What are the clinical implications?
•	These results demonstrate the necessity to measure 
low-density lipoprotein cholesterol and to encourage 
systematic screening for FH at the time of ACS.
•	A better identification of patients with FH after ACS 
is required to individualize the intensity of lipid-
lowering treatment and to better tailor secondary 
prevention because novel lipid-lowering drugs such 
as proprotein convertase subtilisin kexin 9 inhibitors 
are anticipated to further reduce the risk of coro-
nary event recurrence in ACS patients with FH.
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attack, or cerebrovascular or cardiovascular mortality. All car-
diovascular end points used in this analysis were adjudicated 
by a panel of 3 certified cardiologists who served as indepen-
dent experts blinded to the diagnosis of FH.
covariables
Total cholesterol, high-density lipoprotein cholesterol, and 
triglycerides levels were measured in the first blood draw at 
the emergency department within 24 hours of admission and 
immediately processed locally with standardized and certi-
fied dose methods. LDL cholesterol was calculated with the 
Friedewald formula when triglyceride levels were <394 mg/dL. 
LDL cholesterol was considered missing for patients with tri-
glyceride levels of ≥394 mg/dL (1.9% missing). Lipid-lowering 
drugs that were taken before hospitalization and prescribed 
at discharge were systematically collected by trained study 
nurses. For patients using lipid-lowering drugs before hospital-
ization for ACS, we estimated untreated LDL cholesterol levels 
on the basis of the type and dose of lipid-lowering medication 
used before hospitalization, applying a correcting factor for 
LDL cholesterol adapted to the reported efficacy of each drug, 
as done previously for similar analyses.6,14
Pre-existing cardiovascular disease was defined as a previ-
ous diagnosis of CHD, ischemic cerebrovascular disease, or 
peripheral artery disease. Personal history of premature CHD 
was considered positive when men were <55 years old and 
women were <60 years old at the time of first ACS.5 Family 
history of premature CHD was based on patient reports of 
a coronary event in a brother or father <55 years old or a 
mother or sister <60 years old. Education status was dichoto-
mized as having graduated from high school or university or 
having a lower-level education. Hypertension was defined as a 
systolic blood pressure ≥140 mm Hg or diastolic blood pres-
sure ≥90 mm Hg or use of blood pressure–lowering drugs. 
Blood pressure–lowering drugs included all medications in the 
classes of angiotensin-converting enzyme inhibitors, angioten-
sin II receptor blockers, β-blockers, calcium channel blockers, 
diuretics, and nitrates. Smoking status was categorized into 
current, former, and never smokers. Former smokers were 
those who smoked at least 1 cigarette a day during at least 
1 year and were nonsmokers for >1 month before inclusion. 
Diabetes mellitus was either self-reported or diagnosed by the 
use of antihyperglycemic medication or a hemoglobin A1c of 
≥6.5% at admission.
statistical analysis
At the time of hospitalization for ACS, we categorized patients 
according to the presence of FH for each definition and 
reported clinical characteristics in each group, as well as in 
patients not selected by any definition of FH. We assessed the 
associations between FH diagnosis and cardiovascular and 
coronary outcomes using unadjusted and multivariable Cox 
proportional hazard models. In the first model, we adjusted 
only for age and sex. In the second model, we adjusted for 
traditional cardiovascular risk factors, including age, sex, body 
mass index, current smoking, hypertension, and diabetes mel-
litus. In the third model, we further adjusted for high-intensity 
statins at discharge and attendance at cardiac rehabilitation. In 
the final model, we further adjusted for results of the 6-month 
prognosis GRACE (Global Registry of Acute Coronary Events) 
score to account for the severity of ACS. The GRACE risk 
score used to calculate long-term mortality or the composite 
of all-cause mortality or recurrent MI included age, heart rate, 
systolic blood pressure, initial serum creatinine, history of con-
gestive heart failure, history of myocardial infarction, elevated 
cardiac markers (conventional troponins as per local labora-
tories), ST-segment depression, and in-hospital revasculariza-
tion.11,15 In an exploratory analysis, we further adjusted our final 
model to baseline LDL cholesterol levels to examine the role of 
LDL cholesterol in the risk of events among patients with FH. 
We applied a log transformation for LDL cholesterol because 
of right-skewed distribution.
For the coronary and cardiovascular events analysis, first 
events occurring within 1 year after the index hospitalization 
were considered (myocardial infarction, ischemic stroke, tran-
sient ischemic attack, cerebrovascular or cardiovascular mor-
tality, all-cause death), and time to event was censored at 365 
days after the index hospitalization.
To account for age differences between patients with FH 
and those without FH, we additionally assessed the prognosis 
of FH in young patients with premature CHD only and computed 
unadjusted Kaplan-Meier curves. Further sensitivity analyses 
were performed by including only patients who were not using 
lipid-lowering drugs at the time of hospitalization for ACS to 
account for the potential overestimation of FH prevalence with 
this method. All hypothesis tests were 2 sided, and the signifi-
cance level was set at 5%. Statistical analyses were performed 
with STATA 14 (STATA Corp, College Station, TX).
ethics statement
The Medical Ethics Committee of each center (Lausanne, 
Geneva, Bern, and Zurich) approved the study, and all partici-
pants gave written informed consent to participate in the study.
resUlts
Among 4534 patients hospitalized with ACS, 2.5% were 
identified with FH with the American Heart Association 
definition and 5.5% with the Simon Broome definition, 
whereas 18.2% were identified with possible FH and a 
further 1.6% with probable/definite FH with the Dutch 
Lipid Clinic definition. Overall, 79.2% of patients with 
ACS had no criteria for FH. Clinical characteristics of pa-
tients with and without FH are reported in Table 1. Com-
pared with patients without FH, patients with FH were 
<10 years younger and presented more often with a 
first cardiovascular event and an ST-elevation–elevation 
myocardial infarction. Patients with FH identified with the 
American Heart Association definition were older, were 
more frequently women, and presented more frequently 
with hypertension than patients with FH identified with 
other definitions.
During the year after hospitalization for ACS, 153 
patients (3.4%) died, 217 (4.8%) had a fatal or nonfa-
tal myocardial infarction, and 275 (6.1%) experienced 
a cardiovascular event. Unadjusted rates of coronary 
and cardiovascular events were similar between patients 
with and without FH, but patients with FH were 10 years 
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(Continued )
table 1. characteristics of Patients With acs With and Without Fh by Definition (n=4534)
no Fh aha Fh
simon Broome 
Possible Fh
Dutch lipid clinic
Possible Fh
(3–5 Points)
Dutch lipid clinic
Probable/ Definite Fh
(>5 Points)
n 3589 114 250 825 73
Percentage 79.2 2.5 5.5 18.2 1.6
Demographics
 Age, y 66.0 (11.3) 55.6 (11.6) 51.6 (9.8) 52.3 (10.1) 49.8 (9.3)
 Female, n (%) 746 (20.8) 32 (28.1) 55 (22.0) 161 (19.5) 16 (21.9)
 White, n (%) 3389 (94.4) 107 (93.9) 230 (92.0) 766 (92.8) 68 (93.1)
 Higher education, n (%)* 869 (27.9) 29 (28.4) 67 (29.5) 228 (30.4) 21 (30.9)
Smoking status, n (%)
 Never 1168 (32.8) 35 (30.7) 66 (26.4) 199 (24.3) 19 (26.0)
 Former 1121 (31.6) 29 (25.4) 49 (19.6) 149 (18.2) 16 (21.9)
 Current 1263 (35.6) 50 (43.9) 135 (54.0) 472 (57.6) 38 (52.1)
Elevated alcohol use† 450 (14.1) 12 (11.5) 24 (10.5) 94 (12.4) 9 (13.2)
Comorbidities
 Hypertension‡ 2173 (60.6) 52 (45.6) 101 (40.4) 318 (38.5) 28 (38.4)
 Diabetes mellitus§ 711 (19.8) 9 (7.9) 28 (11.2) 81 (9.8) 4 (5.5)
 Pre-existing CVD‖ 955 (26.6) 17 (14.9) 33 (13.2) 133 (16.1) 8 (11.0)
 Premature CHD¶ 611 (17.0) 62 (54.4) 197 (78.8) 660 (80.0) 65 (89.0)
 Family history# 643 (17.9) 114 (100) 118 (47.2) 452 (54.8) 57 (78.1)
Objective measures
 Total cholesterol, mg/dL 181.7 (42.5) 270.7 (50.3) 274.6 (50.3) 224.3 (42.5) 290.0 (61.9)
 LDL cholesterol, mg/dL 123.7 (34.8) 224.3 (50.3) 224.3 (42.5) 166.3 (42.5) 255.2 (65.7)
 HDL cholesterol, mg/dL 46.4 (15.5) 46.4 (11.6) 42.5 (11.6) 42.5 (11.6) 42.5 (11.6)
 Triglycerides, mg/dL 122.5 (96.2) 122.5 (52.5) 148.7 (113.7) 131.2 (105.0) 113.7 (43.7)
 Body mass index, kg/m2 27.0 (4.3) 27.5 (4.8) 27.6 (4.5) 27.4 (4.4) 28.2 (5.1)
eGFR, mL/min 86.9 (27.2) 90.9 (19.9) 94.4 (23.4) 98.8 (24.6) 92.8 (19.6)
Medication at admission, n (%)
 Aspirin 1132 (31.6) 34 (29.8) 60 (24.0) 157 (19.0) 25 (34.2)
 Lipid-lowering drugs** 1064 (29.6) 43 (37.7) 83 (33.2) 188 (22.8) 31 (42.5)
 Statins 1036 (28.9) 40 (35.1) 79 (31.6) 184 (22.3) 28 (38.4)
 Antihypertensives†† 1810 (50.4) 37 (32.5) 70 (28.0) 228 (27.6) 22 (30.1)
Type of ACS (n=4516), n (%)
 STEMI 1886 (52.8) 65 (57.0) 148 (59.2) 462 (56.2) 46 (63.0)
 NSTEMI 1528 (42.7) 45 (39.5) 95 (38.0) 325 (39.5) 24 (32.9)
 Unstable angina 160 (4.5) 4 (3.5) 7 (2.8) 35 (4.3) 3 (4.1)
Severity of ACS
 Killip class III or above, n (%) 156 (4.3) 2 (1.7) 4 (1.6) 25 (3.0) 0 (0)
 Cardiac arrest, n (%) 140 (3.9) 3 (2.6) 8 (3.2) 3 (0.4) 0 (0)
  GRACE score for 6-mo 
mortality, points (n=4279)‡‡
139 (25) 121 (22) 114 (21) 116 (22) 114 (20)
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younger (Table 2 and Figure 1). In a multivariable model 
adjusted for age, sex, body mass index, current smok-
ing, hypertension, diabetes mellitus, pre-existing cardio-
vascular disease, attendance at cardiac rehabilitation, 
prescription of high-intensity statins at discharge, and re-
sults of the 6-months GRACE risk score, patients with FH 
had a 2.46 increased risk of a recurrent coronary event 
compared with patients without FH (hazard ratio, 2.46; 
95% confidence interval, 1.07–5.65; P=0.034) with the 
American Heart Association definition. The multivariable 
hazard ratio was 2.73 (95% confidence interval, 1.46–
5.11; P=0.002) with the Simon Broome definition, and 
3.53 (95% confidence interval, 1.26–9.94; P=0.017) 
with the probable/definite Dutch Lipid Clinic definition. 
For cardiovascular events, point estimates of the mul-
tivariable hazard ratio were slightly lower and reached 
statistical significance only with the Simon Broome 
definition (hazard ratio, 2.49; 95% confidence interval, 
1.43–4.34; P=0.046). Further adjustment of the multi-
variable model with baseline LDL cholesterol levels did 
not decrease the point estimates of hazard ratios for 
coronary or cardiovascular events.
Comparisons of lipid management after ACS are 
reported in Table 3 for patients with and without FH. 
Among patients identified with FH according to at least 1 
definition, 98.6% were discharged with any statins, and 
77.3% were discharged with high-dose statins. One year 
after ACS, high-dose statins were still used by >70% of 
patients with FH, but <10% scored the 70-mg/dL LDL 
cholesterol target. Among patients without FH, 67% 
were discharged with high-dose statins, and 56% were 
still on high-dose statins 1 year after ACS, with nearly 
38% reaching the 70-mg/dL LDL cholesterol target.
Stratified analyses performed in 1369 patients with 
premature CHD showed an increased risk of coronary 
events for patients with FH compared with patients 
without FH in both the unadjusted and multivariable-
adjusted models (Table 4 and Figure 2). For cardiovas-
cular events, statistical significance was reached for 
the Simon Broome definition only. Restricting the analy-
sis to 3234 patients not using lipid-lowering drugs at 
baseline yielded roughly similar risk estimates but with 
larger confidence intervals (Table IV in the online-only 
Data Supplement).
DiscUssiOn
In this multicenter, observational study, the prevalence 
of FH was 1.6% to 5.5% (depending on which clinical 
definition of FH was used) among patients hospitalized 
Severity of coronary lesions, n (%)
  ≥2 Treated coronary lesions 
(n=4227)
1198 (36.0) 30 (27.3) 64 (26.7) 225 (28.7) 17 (25.0)
  ACC/AHA classification grade 
B2 or C any lesion (n=3497)
1100 (39.7) 29 (31.9) 69 (33.7) 216 (34.0) 21 (38.2)
  TIMI grade flow 0–II before PCI 
(n=3474)§§
1843 (67.6) 64 (71.1) 139 (66.8) 461 (70.3) 43 (72.9)
  TIMI grade flow 0–II after PCI 
(n=3480)§§
118 (4.3) 2 (2.2) 7 (3.4) 23 (3.5) 1 (1.7)
Data are given as mean (SD) when appropriate. ACC indicates American College of Cardiology; ACS, acute coronary syndrome; AHA, American Heart 
Association; eGFR, estimated glomerular filtration rate; FH, familial hypercholesterolemia; GRACE, Global Registry of Acute Coronary Events; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; NSTEMI, non–ST-segment–elevation myocardial infarction; PCI, percutaneous coronary intervention; 
STEMI, ST-segment–elevation myocardial infarction; and TIMI, Thrombolysis in Myocardial Infarction. 
*Defined as a high school or university graduation or higher.
†Defined as >14 units of alcohol a week.
‡Defined as a systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg or use of blood pressure–lowering drugs.
§Based on patient self-report, use of antihyperglycemic medication/insulin, or hemoglobin A
1c
 ≥6.5%.
‖Defined as coronary heart disease, ischemic cerebrovascular disease, or peripheral artery disease.
¶Age of onset for ACS <55 years in men and <60 years in women.
#Self-reported history of a major cardiovascular event in a brother or father <55 years old or a mother or sister <60 years old.
**Include statins, fibrates, ezetimibe, niacin, and resins.
††Include angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β-blockers, calcium channel blockers, or diuretics.
‡‡Include age, heart rate, systolic blood pressure, initial serum creatinine, history of congestive heart failure, history of myocardial infarction, elevated 
cardiac markers (conventional troponins as per local laboratories), ST-segment depression, and in-hospital revascularization.
§§Lowest TIMI flow per patient.
table 1. continued
no Fh aha Fh
simon Broome 
Possible Fh
Dutch lipid clinic
Possible Fh
(3–5 Points)
Dutch lipid clinic
Probable/ Definite Fh
(>5 Points)
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for ACS, which demonstrates that the prevalence of FH 
may be 3 to 10 times greater than in the general popula-
tion.16,17 We further reported that patients with FH identi-
fied with clinical criteria had a >2-fold increase in risk of 
recurrent coronary events within 1 year after discharge 
compared with patients without FH after multivariable ad-
justment and despite more frequent use of high-intensity 
statins. This association between FH clinical diagnosis 
and recurrent coronary events was independent of car-
diovascular risk factors and severity of ACS.
Previous studies assessed the cardiovascular risk 
of patients with FH compared with population-based 
table 2. risks of recurrent events after acs With respect to the Presence of Fh (n=4534)
aha Definition simon Broome Definition Dutch lipid clinic Definition
no Fh Fh no Fh Possible Fh
no Fh
(score <3)
Possible Fh
(score 3–5)
Probable/
Definite Fh
(score >5)
Coronary events
 Events/participants, n 211/4420 6/114 205/4284 12/250 185/3636 28/825 4/73
  Incidence rate, per 100 
person-y
5.0 5.6 5.0 5.0 5.4 3.5 5.7
 Unadjusted HR (95% CI) 1.00
(Referent)
1.10
(0.49;2.48)
1.00
(Referent)
0.99
(0.55–1.78)
1.00
(Referent)
0.66
(0.44–0.98)
1.07
(0.40–2.87)
  Age/sex–adjusted HR  
(95% CI)
1.00
(Referent)
1.65
(0.73–3.76)
1.00
(Referent)
1.95
(1.06–3.58)
1.00
(Referent)
1.32
(0.86–2.03)
2.55
(0.92–7.03)
  Model 1 adjusted HR  
(95% CI; n=4465)*
1.00
(Referent)
1.99
(0.87–4.53)
1.00
(Referent)
2.27
(1.23–4.18)
1.00
(Referent)
1.51
(0.97–2.35)
3.14
(1.13–8.71)
  Model 2 adjusted HR  
(95% CI; n=4423)†
1.00
(Referent)
2.33
(1.02–5.34)
1.00
(Referent)
2.51
(1.35–4.68)
1.00
(Referent)
1.60
(1.00–2.56)
3.44
(1.23–9.63)
  Model 3 adjusted HR  
(95% CI; n=4175)‡
1.00
(Referent)
2.46
(1.07–5.65)
1.00
(Referent)
2.73
(1.46–5.11)
1.00
(Referent)
1.54
(0.94–2.52)
3.53
(1.26–9.94)
  Model 3 additionally 
adjusted for LDL cholesterol, 
HR (95% CI; n=4094)
1.00
(Referent)
2.92
(1.23–6.99)
1.00
(Referent)
3.73
(1.89–7.38)
1.00
(Referent)
1.92
(1.13–3.25)
5.13
(1.71–15.43)
Cardiovascular events
 Events/participants, n 267/4420 8/114 259/4284 16/250 236/3636 35/825 4/73
  Incidence rate, per 100 
person-y
6.4 7.5 6.4 6.7 6.9 4.4 5.7
 Unadjusted HR (95% CI) 1.00
(Referent)
1.17
(0.58–2.36)
1.00
(Referent)
1.05
(0.63–1.74)
1.00
(Referent)
0.64
(0.45–0.92)
0.83
(0.31–2.23)
  Age/sex–adjusted HR  
(95% CI)
1.00
(Referent)
1.72
(0.84–3.50)
1.00
(Referent)
2.02
(1.19–3.42)
1.00
(Referent)
1.25
(0.85–1.84)
1.88
(0.67–5.16)
  Model 1 adjusted HR  
(95% CI; n=4465)*
1.00
(Referent)
2.06
(1.01–4.21)
1.00
(Referent)
2.34
(1.37–3.97)
1.00
(Referent)
1.44
(0.97–2.13)
2.31
(0.84–6.34)
  Model 2 adjusted HR  
(95% CI; n=4423)†
1.00
(Referent)
1.98
(0.92–4.25)
1.00
(Referent)
2.31
(1.33–4.01)
1.00
(Referent)
1.47
(0.97–2.22)
2.46
(0.89–6.80)
  Model 3 adjusted HR  
(95% CI; n=4175)‡
1.00
(Referent)
2.08
(0.97–4.48)
1.00
(Referent)
2.49
(1.43–4.34)
1.00
(Referent)
1.44
(0.94–2.21)
2.49
(0.90–6.91)
  Model 3 additionally 
adjusted for LDL cholesterol, 
HR (95% CI; n=4094)
1.00
(Referent)
2.39
(1.08–5.31)
1.00
(Referent)
3.27
(1.79–5.97)
1.00
(Referent)
1.71
(1.08–2.70)
3.32
(1.14–9.69)
ACS indicates acute coronary syndrome; AHA, American Heart Association; CI, confidence interval; FH, familial hypercholesterolemia; HR, hazard ratio; 
and LDL, low-density lipoprotein.
*Adjusted for age, sex, and cardiovascular risk factors, including body mass index, current smoking, hypertension, diabetes mellitus, and pre-existing 
cardiovascular disease.
†Model 1 additionally adjusted for prescription of high-intensity statins and attendance at cardiac rehabilitation at discharge.
‡Model 2 additionally adjusted for results of the 6-month GRACE (Global Registry of Acute Coronary Events) risk score.
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cohorts from the general population, but none prospec-
tively compared the recurrence of cardiovascular events 
after CHD in patients with or without FH, nor did they 
adjust the prognosis of FH according to cardiovascular 
risk factors and severity of CHD. The Simon Broome 
Register Group reported mortality rates of patients with 
FH.18–20 These studies were conducted mainly in primary 
prevention, and ≈70% of men and 80% of women had 
no pre-existing CHD at the beginning of follow-up. How-
ever, the benefit of statins may differ between primary 
and secondary prevention among patients with FH.20 Fur-
thermore, recommendations for clinical management of 
patients with FH and CHD should also be based on the 
recurrence of nonfatal clinical events. One study carried 
out in Dutch lipid clinics prospectively examined the rates 
of coronary events in patients with FH without a record 
of pre-existing cardiovascular disease.9 Other studies in 
Dutch lipid clinics were retrospective or cross-sectional, 
and cardiovascular risk estimates may have been prone 
to confounding biases.14,21 One prospective study in a 
single lipid clinic in the Netherlands examined the risk of 
recurrence of cardiovascular events in 131 patients with 
FH and pre-existing CHD who were treated with statins.10 
However, they did not adjust recurrence estimates to 
cardiovascular risk factors, statin dose, or severity of 
CHD. To the best of our knowledge, our study is the first 
to prospectively assess the risk of coronary and cardio-
vascular event rates in a large cohort of patients with FH 
after ACS who were treated with high-intensity statins.
Despite wide implementation of high-dose statins af-
ter ACS, patients with FH remain at increased risk of 
recurrence compared with patients without FH after ac-
counting for age. In clinical practice, the implementation 
of a systematic screening strategy for FH is limited by 
the costs of genetic testing and counseling.22 Because 
cardiovascular risk was shown to be driven by both 
phenotype and genotype,21,23 expert groups proposed 
simplified definitions for establishing a diagnosis of FH 
based on clinical criteria.1–3 In our study, we were able to 
demonstrate how these simplified screening algorithms 
using cholesterol levels and family or personal history of 
premature CHD as diagnostic criteria were powerful and 
efficient tools to identify FH in patients with ACS at high 
risk of coronary event recurrence despite high-intensity 
statin treatments. Furthermore, treatments other than 
lipid-lowering drugs such as dual antiplatelet therapy 
Figure 1. incidence of recurrent coronary events after acute coronary syndrome by presence of familial hyper-
cholesterolemia (Fh; n=4534).  
A, American Heart Association definition of FH. B, Simon Broome Register definition of FH. C, Dutch Lipid Clinic definition of FH.
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were prescribed more often in patients with FH than in 
those without FH. Patients with FH also had better coro-
nary flow after percutaneous coronary intervention than 
patients without FH. Overall, these factors may have led 
to underestimation of the risk ratios we reported.
We also reported that additional adjustment with base-
line LDL cholesterol at the time of ACS did not further re-
duce the risk gap between patients with and without FH. 
From these results, we propose that the elevated cardio-
vascular risk in ACS patient with FH may be explained by 
lifelong persistence of elevated LDL cholesterol levels, 
as well as familial susceptibility to atherosclerosis.
Novel lipid-lowering drugs such as proprotein conver-
tase subtilisin kexin 9 inhibitors are anticipated to further 
reduce the risk of cardiovascular disease in patients with 
heterozygous FH, in whom low levels of LDL cholesterol 
cannot be achieved with statins only.24,25 However, in 
light of the high cost of proprotein convertase subtili-
sin kexin 9 inhibitors, prescription strategies for these 
drugs will need to target specifically those adults most 
likely benefit from intensified lipid management such as 
patients with FH.26 The benefit of systematically identi-
fying patients with FH at the time of hospitalization for 
ACS to reduce the recurrence of cardiovascular events 
still needs to be demonstrated. Nevertheless, FH is a 
frequent disorder among patients with ACS, with preva-
lence rates reaching 15% in some studies.5,6,27,28 Sys-
tematic screening for FH based on clinical criteria has 
been shown to be easy to carry out and affordable. With 
the added benefits that proprotein convertase subtilisin 
kexin 9 inhibitors are expected to bring in terms of car-
diovascular events reduction, systematic screening for 
FH should be encouraged in patients with ACS until fur-
ther evidence is available.
Our study has strengths and limitations. Our results 
have strong external validity because our study popula-
tion was derived from nonselected patients with ACS 
in 4 different centers, in contrast to previous studies 
that were conducted mainly in lipid clinics.10,14,18,19 How-
ever, the increased recurrence risk of coronary events 
table 3. comparison of clinical Management after acs Between Patients With and Without Fh by Definition 
(n=4534)
no Fh aha Fh
simon Broome 
Possible Fh
Dutch lipid clinic
Possible Fh
(3–5 Points)
Dutch lipid clinic
Probable/Definite Fh
(>5 Points)
n 3,589 114 250 825 73
Acute revascularization (n=4498), n (%)
 PCI 3186 (89.5) 106 (93.0) 232 (93.2) 757 (92.4) 63 (86.3)
 CABG 91 (2.6) 1 (0.9) 1 (0.4) 13 (1.6) 0 (0.0)
Lipid-lowering drugs at discharge (n=4481), n (%)
 Statins 3,456 (97.6) 112 (99.1) 245 (98.4) 811 (98.9) 69 (94.5)
  High-dose statins* 2,383 (67.3) 93 (82.3) 202 (81.1) 633 (77.2) 54 (74.0)
   Other lipid-lowering agents† 53 (1.5) 8 (7.1) 12 (4.8) 18 (2.2) 7 (9.6)
Secondary prevention, n (%)
  Cardiac rehabilitation (n=4482) 2,258 (63.8) 90 (79.6) 195 (78.3) 626 (76.2) 57 (78.1)
 P2Y12 inhibitors (n=3821)‡ 2,887 (96.4) 98 (99.0) 221 (99.1) 707 (97.4) 61 (100)
Lipid-lowering drugs at 1 y (n=4204), n (%)
 Statins 3,083 (93.2) 102 (93.6) 223 (94.9) 739 (94.0) 67 (94.4)
  High-dose statins* 1,856 (56.1) 77 (70.6) 167 (71.1) 501 (63.7) 50 (70.4)
   Other lipid-lowering agents† 143 (4.3) 17 (15.6) 37 (15.7) 69 (8.8) 14 (19.7)
Lipid values at 1 y (n=2345)
  LDL cholesterol, mean (SD), mg/dL 82.9 (31.3) 119.4 (45.9) 112.3 (39.9) 93.7 (35.0) 125.5 (46.8)
  LDL ≤70 mg/dL, n (%) 687 (37.7) 5 (8.8) 13 (9.8) 101 (22.5) 2 (4.5)
  LDL ≤100 mg/dL, n (%) 1,375 (75.4) 28 (49.1) 62 (47.0) 299 (66.7) 16 (36.4)
ACS indicates acute coronary syndrome; AHA, American Heart Association; CABG, coronary artery bypass graft; FH, familial hypercholesterolemia; LDL, 
low-density lipoprotein; and PCI, percutaneous coronary intervention.
*High-dose statins included atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg.
†Lipid-lowering agents other than statins included fibrates, niacin, ezetimibe, and bile acid resins.
‡Prescription of clopidogrel, prasugrel, or ticagrelor in addition to aspirin after PCI with a stent.
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applies only to patients with ACS with FH. Despite the 
fact that we adjusted our estimate to the severity of 
ACS, selection bias of patients with FH who have some 
unmeasured confounder leading them to be hospital-
ized at varying rates than patients without FH also is 
possible.29 We were not able to assess the concordance 
of the rates of FH measured according to the clinical 
definitions we chose for its diagnosis with the results of 
genetic testing for FH. Because clinical criteria without 
molecular diagnosis may overestimate the prevalence 
of FH, many of our patients classified as having FH may 
in fact have polygenic hypercholesterolemia.23,30 This 
misclassification could, in turn, have underestimated 
the cardiovascular risk of patients classified as FH, as 
suggested by the greater risk ratio associated with FH 
compared with polygenic hypercholesterolemia in the 
probable/definite category of the Dutch Lipid Clinic defi-
nition. In other words, patients with a confirmed genetic 
diagnosis of FH may be at even greater risk of cardio-
vascular events than what we found in our study. Further-
more, we did not collect data on family history of high 
LDL cholesterol levels or on skin manifestations such 
as xanthoma. Overall, these missing data decreased 
the sensitivity of the Simon Broome and the Dutch Lipid 
Clinic definitions. On the other hand, we found a consis-
tent association between FH and cardiovascular events 
across all 3 clinical definitions for FH.31 Also of note is 
that LDL cholesterol levels are lowered 12 to 24 hours 
after an ACS, another cause that could have led to the 
prevalence of FH being underestimated in our study.32,33 
This potential misclassification of FH may, in turn, have 
decreased the relative incremental risk associated with 
FH. Finally, we used self-reported information on family 
history of premature CHD, and a recall bias may have 
occurred in patients with ACS, leading to an overestima-
tion of FH prevalence. However, recent data presented 
by others showed similar reporting accuracy of family 
history in patients with and without pre-existing cardio-
vascular disease.34
cOnclUsiOns
Patients with FH hospitalized for ACS are at high risk of 
coronary event recurrence after discharge despite the 
table 4. risks of recurrent events in Young Patients With Premature acs With respect to Presence of Fh 
(n=1369)
aha Definition simon Broome Definition Dutch lipid clinic Definition
no Fh Fh no Fh Possible Fh
no Fh
(score <3)
Possible Fh
(score 3–5)
Probable/
Definite Fh
(score >5)
Coronary events
 Events/participants, n 31/1307 4/62 25/1172 10/197 11/644 20/660 4/65
 Incidence rate, per 100 person-y 2.4 6.9 2.2 5.3 1.7 3.1 6.4
 Unadjusted HR (95% CI) 1.00
(Referent)
2.78
(0.98–7.88)
1.00
(Referent)
2.39
(1.15–4.99)
1.00
(Referent)
1.78
(0.86–3.72)
3.66
(1.17–11.50)
  Age/sex–adjusted HR (95% CI) 1.00
(Referent)
3.02
(1.06–8.57)
1.00
(Referent)
2.54
(1.22–5.29)
1.00
(Referent)
1.86
(0.89–3.88)
3.85
(1.23–12.12)
  Multivariable-adjusted HR  
(95% CI; n=1283)*
1.00
(Referent)
2.95
(1.03–8.49)
1.00
(Referent)
2.72
(1.29–5.75)
1.00
(Referent)
1.59
(0.74–3.38)
3.71
(1.16–11.81)
Cardiovascular events
 Events/participants, n 41/1307 4/62 33/1172 12/197 16/644 25/660 4/65
  Incidence rate, per 100 
person-y
3.2 6.9 2.9 6.4 2.6 3.9 6.4
 Unadjusted HR (95% CI) 1.00
(Referent)
2.09
(0.75–5.84)
1.00
(Referent)
2.18
(1.13–4.22)
1.00
(Referent)
1.54
(0.82–2.88)
2.51
(0.84–7.50)
 Age/sex–adjusted HR (95% CI) 1.00
(Referent)
2.24
(0.80–6.26)
1.00
(Referent)
2.29
(1.18–4.43)
1.00
(Referent)
1.59
(0.85–2.98)
2.63
(0.88–7.88)
  Multivariable-adjusted HR  
(95% CI; n=1283)*
1.00
(Referent)
2.16
(0.76–6.13)
1.00
(Referent)
2.44
(1.24–4.79)
1.00
(Referent)
1.42
(0.74–2.71)
2.66
(0.87–8.12)
AHA indicates American Heart Association; CI, confidence interval; FH, familial hypercholesterolemia; and HR, hazard ratio.
*Adjusted for age, sex and cardiovascular risk factors, including body mass index, current smoking, hypertension, diabetes mellitus, pre-existing 
cardiovascular disease, high-intensity statins at discharge, attendance to cardiac rehabilitation at discharge, and results of the 6-months GRACE (Global 
Registry of Acute Coronary Events) risk score.
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use of high-dose statins. In the era of systematic prescrip-
tion of high-dose statins, measuring cholesterol levels at 
the time of ACS diagnosis has been considered superflu-
ous. On the other hand, our results suggest that patients 
with FH need to be identified because they are less likely 
to reach target LDL cholesterol levels. Proper identifica-
tion of patients with FH will also be useful for testing new 
approaches in individualized treatment such as novel lipid-
lowering drugs, family counseling, and tailored secondary 
prevention. Finally, the intensification of lipid management 
and secondary prevention in patients with FH may reduce 
the recurrence of cardiovascular events.
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Table 1 
American Heart Association criteria for clinical diagnosis of familial hypercholesterolemia (FH) (n=4,534) 
 
 
 
 
 
 
 
 
NA, not available 
LDL-cholesterol >4.9 mmol/l
 
AND Grading 
% subject 
scoring 
(number) 
 First degree relative with known premature coronary heart disease 
(< 55 years men; < 60 years women)  
FH 
2.5 
(114) 
 
First-degree relative with LDL-cholesterol > 4.9 mmol/l FH NA 
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Table 2  
Simon Broome Register criteria adapted from NICE guidelines for diagnosis of familial hypercholesterolemia (FH) (n=4,534) 
 
 
 
 
 
 
 
 
 
 
 
NA, not available 
Total cholesterol > 7.5 mmol/l  OR  LDL-cholesterol >4.9 mmol/l
 
AND Grading 
% subject 
scoring 
(number) 
 
First degree relative with known premature coronary heart disease  
(< 55 years men; < 60 years women)  
Possible 
FH 
2.6 
(118)  
 
 
Personal history of premature coronary heart disease (< 55 years 
men; < 60 years women) 
Possible 
FH 
4.3 
(197) 
 
 
Tendon xanthomas  
Definite 
FH 
NA 
 
DNA mutation 
Definite 
FH 
NA 
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Table 3 
Dutch Lipid Clinic Network criteria for diagnosis of familial hypercholesterolemia (FH) 
(n=4,534) 
 
Variable Grading 
% subject 
scoring 
(number) 
First degree relative with known premature atherosclerosis OR  
with known LDL-cholesterol > 95
th
 percentile, OR personal 
history of  premature (< 55 years men; < 60 years women) 
cerebral or peripheral vascular disease, OR  LDL-cholesterol 4.0-
4.9 mmol/l
*
  
1 point 
37.3 
(1,691)  
 
Personal history of premature (< 55 years men; < 60 years 
women) coronary heart disease OR first-degree relative with 
tendon xanthomata and/or arcus cornealis OR  first-degree relative 
child below 18 years with LDL-cholesterol > 95
th
 percentile OR 
2 points 
30.2 
( 1,369 ) 
 
LDL-cholesterol 5.0-6.4 mmol/l
*
  3 points 
5.8 
(261) 
Presence of arcus cornealis below 45 years 4 points NA 
LDL-cholesterol 6.5-8.4 mmol/l
*
 5 points 
1.0 
(45) 
Presence of tendon xanthomata  6 points NA 
LDL-cholesterol > 8.5 mmol/l
*
 OR  functional mutation in LDL 
receptor gene present 
8 points 
0.09  
(4)  
   
 
5 
 
NA, not available 
*
Only in those with triglyceride levels < 2.3 mmol/l 
Possible FH: 3-5 points; probable FH: 6-7 points; definite FH >= 8 points 
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1
Adjusted for age, sex and cardiovascular risk factors, including body mass index, current smoking, hypertension, diabetes mellitus, 
pre-existing cardiovascular disease, high-intensity statins at discharge, attendance to cardiac rehabilitation at discharge, and results of 
the 6-months GRACE risk score. 
Abbreviations: AHA, American Heart Association ; HR, hazard ratio; CI, confidence interval; GRACE, Global Registry of Acute 
Coronary Events 
Table 4 – Risks of recurrent events after acute coronary syndrome (ACS), with respect to presence of familial hypercholesterolemia (FH) in patient 
not using lipid-lowering drugs at admission (n=3,234) 
 
AHA definition Simon Broome definition Dutch Lipid Clinic definition 
No FH FH No FH Possible FH 
No FH 
(score <3) 
Possible FH 
(score 3-5) 
Probable/defi
nite FH 
(score > 5) 
Coronary events        
 Number of events/participants 125/3,163 4/71 122/3,067 7/167 109/2,555 18/637 2/42 
Age sex adjusted HR (95% CI) 1.00 
(ref) 
2.02 
(0.74;5.51) 
1.00 
(ref) 
1.92 
(0.87;4.23) 
1.00 
(ref) 
1.30 
(0.75; 2.25) 
2.56 
(0.61;10.65) 
Multivariable-adjusted HR (95% 
CI)
1 
(n= 1,283) 
1.00 
(ref) 
2.97 
(1.07;8.27) 
1.00 
(ref) 
2.70 
(1.19;6.12) 
1.00 
(ref) 
1.30 
(0.69;2.47) 
3.21 
(0.75;13.68) 
Cardiovascular events 
       
 Number of events/participants 161/3,163 5/71 157/3,067 9/167 143/2,555 21/637 2/42 
Age sex adjusted HR (95% CI) 1.00 
(ref) 
1.89 
(0.77;4.63) 
1.00 
(ref) 
1.82 
(0.91;3.65) 
1.00 
(ref) 
1.07 
(0.64; 1.74) 
1.73 
(0.42;7.15) 
Multivariable-adjusted HR (95% 
CI)
1 
(n= 2,993) 
1.00 
(ref) 
1.98 
(0.72;5.44) 
1.00 
(ref) 
2.05 
(0.97;4.35) 
1.00 
(ref) 
1.01 
(0.57; 1.79) 
2.01 
(0.48;8.42) 
 
Carolyn: Welcome to Circulation On The Run, your weekly podcast, summary and backstage pass 
to the journal and its editors. I'm Dr. Carolyn Nam, associate editor from the national 
heart center and Duke National University of Singapore. 
 
 In just a while, we will be discussing patients with familial hypercholesterolemia after 
acute coronary syndrome, and the new data in this week's issue that suggests we still 
need to pay special attention to this group of patients even in the current era of the 
widespread use of high intensity satins. First here's your summary of this weeks issue. 
 
 The first paper suggests that we may need to look at thyroid function in our risk 
assessment sudden cardiac death in the general population. This paper is from co 
primary authors Dr. Chacker in Van Der Burgh and corresponding author Dr. Strecker 
and colleagues from the Erasmus University medical center in water dom. 
 
 The authors studied the association of thyroid function with sudden cardiac death in 
more than 10,000 participants of the population based Water Dom study. They found 
the higher levels of 3T4 were associated with an increased risk of sudden cardiac death 
even in the normal range of thyroid function. The estimated hazard ratio was 2.28 per 
one nano-gram per deciliter of 3T4, and these risk estimates did not change 
substantially even after stratification by age or sex or sensitivity analysis excluding 
participants with an abnormal 3T4. The absolute 10 year risk of sudden cardiac death 
increased in youth thyroid participants from 1 to 4% within increasing 3T4 levels. 
 
 Thus this study suggests that 3T4 and additive marker in risk stratifications for sudden 
cardiac death in the general population. Further research is needed to assess the 
possible additional benefit of using 3T4 levels to re stratify and prevent sudden cardiac 
death. 
 
 The next study reminds us that therapies to reduce ischemic events in patients 
undergoing percutaneous coronary intervention are still really important even in the 
current era of changing definitions of periprocedural myocardial infarction. This study is 
from first author Dr. Cavender of University of North Carolina chapel hill and 
corresponding author Dr. Bach Brigham women's hospital and colleagues. 
 
 The authors looked at more than 11,000 patients randomized to cangrelor or 
clopidogrel int the champion phoenix trial. 
 
 Cangrelor is an intravenous P2Y-12 inhibitor approved to reduce periprocedural 
ischemic events in patients undergoing percutaneous coronary intervention who are not 
pretreated with with a P2Y-12 inhibitor. 
 
 The authors explored the effects of cangrelor on myocardial infarction using different 
definitions of myocardial infarction and perform sensitivity analysis on primary 
endpoint. 
 
 They found that 4.2 percent of patients had a myocardial infarction defined by the 
second universal definition within 48 hours after undergoing PCI. When the sky 
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definition of periprocedural MI was used, there were fewer total myocardial infarction, 
but the effects of cangrelor remain significant. 
 
 Finally similar effects were seen when MI's were restricted to those defined with large 
bio marker elevations or by symptoms of ECG changes. Very importantly patients who 
had an MI regardless of the definition, were at increased risk of death at 30 days. 
 
 In summary changes in the definition of MI used in the primary endpoint did not affect 
the overall findings from the champion phoenix trial. This study also reminds us that 
periprocedural MI remains an important clinical event in the current era. Being 
associated with increased risks of death at 30 days, and therefore reducing ischemic 
events in patients undergoing PCI remains very important. 
 
 The final paper describes experimental evidence of a novel treatment approach to 
hypertension using micro RNA's. This paper is from first author Dr. Lee and 
corresponding authors Dr. Chinn and Wang from Tong G medical college and Whadrom 
University of Science and Technology in Wuhan China. 
 
 Micro RNA's are a class of small non-coding RNA's that regulate gene expression at a 
post transcriptional level. These authors compared the expression of key neucler 
genoman coded and mitochondrial genoman coded genes involved reactive oxygen 
species production in spontaneous hypertensive rats and wistar rats. They then used 
bioinformatics to predict the micro RNA targets followed by biochemical validation using 
real time PCR and immunial precipitation. 
 
 They first found that there was down regulation of mitochondrial DNA encoded sitoca B 
in the spontaneous hyper intensive rats, which appeared to directly contribute to the 
increased mitochondrial reactive oxygen species. 
 
 Next they found that mere 21 a key micro RNA induced into hyper spontaneous rats, 
was able to trans-locate into mitochondria to counteract the mitochondria pseudonym 
B down regulation. Finally, they showed that exogenous mere 21 delivered by 
recombinant adeno associated virus was able to lower blood pressure and attenuate 
cardiac hypertrophy in the spontaneously hypertensive rat model. 
 
 These findings are striking because they provide experimental support for developing 
micro RNA based treatments for hypertension. 
 
 Those were your summaries of original papers but before I go, I just have to highlight 
this in depth review paper in this week's issue, and it is regarding sodium glucose co 
transported to inhibitors or SLG2 inhibitors in the treatment of diabetes, discussing the 
cardiovascular and kidney affects potential mechanisms and clinical applications. 
 
 It is a beautiful review article written by first author Dr. Heresphink of the University 
Medical Center Groningen, corresponding author Dr. Churney from Toronto general 
hospital and colleagues. Truly a must read, but now here is our featured paper. 
 
  
 
 
 
 Page 3 of 6 
 
 Our featured paper today is on patients with familial hypercholesterolemia after acute 
cornery syndromes. Today I have with us the first and corresponding author David Nan 
chin university of Lausanne in Switzerland. 
 
 Hi David, thanks for joining us. 
 
David: Hi, I'm very happy to be here. 
 
Carolyn: As the associate editor who managed this paper we have Dr. Amat Kira and you will 
recognise him as the digital strategies editor as well from UT Southwestern. Welcome 
back Amat. 
 
Amat: Thank You Carolyn, happy to be here. 
 
Carolyn: I am really curious about this paper because it speaks of familial hypercholesterolemia 
that most of us would assume is very rare. 
 
 Now David, I know that you actually published prevalence in a prior paper last year, but 
could you maybe start by telling us why we should, how common is this in our patients 
with acute coronary syndrome? 
 
David: In fact we studied patients who is hospitalized with acute coronary syndrome in several 
university hospitals in Switzerland. Of course we try our best to include all classifications 
in the study in order to be very protective of the acute coronary syndrome population. 
 
 We found that among patients with acute coronary syndrome, familial 
hypercholesterolemia was not a rare disease. We found a prevalence of 2-5% which is in 
fact 10 times higher than what is thought to be in the general population. 
 
 The important point here is that we use very simple clinical catatonia to assist the 
prevalence of adage. This catatonia includes unbelievable[inaudible 00:08:50] and the 
family of Bethany of coronary heart disease. This criteria are very easy to use and 
implement in a clinical practice in the sitting in acute coronary syndrome to detect 
patients with familial hypercholesterolemia. 
 
Carolyn: Exactly. You did not use molecular diagnosis in your paper, but yet, with these simple 
criteria there was a very important clinical take home message. Could you tell us about 
those findings? 
 
David: The question we wanted to answer here is wanted to know what happened to this 
patient with familial hypercholesterolemia after hospital discharge. We found that 
patients with familial hypercholesterolemia were an increased risk of recurrence of 
cornea events within the year after discharge, and this is despite the use of idol science. 
 
 In fact, one year after the coronary syndrome, 7 people found a patient with adage were 
still using idle studies, which is very good we were quite impressed by these numbers, 
but they mean[inaudible 00:09:57] one year after the acute coronary syndrome, with 
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one in twenty become affected later. 
 
 Most of these patients were not able to decrease their added cholesterol to lower 
evens. 
 
 I really think there is clear room for infestation of leamington therapy among these 
patients. In any of those drugs available from my seeing and very effective to decrease 
and [inaudible 00:10:25] to substance, but they are very expensive. 
 
 Maybe the best initial strategy, to prescot these drugs, is to target patients with familial 
hypercholesterolemia after acute coronary syndrome. Because these patients are at 
high risk of recurrence and most of them cannot achieve their cholesterol level with our 
studies. 
 
Carolyn: Congratulations for being really the first to show that. This is common and it affects 
recurrent events. I think actually the first step is to recognize this in our patients which 
very few of us really do I think. 
 
 Amat from your point of view, knowing the results of this paper how has it changed 
your clinical practice? 
 
Amat: Absolutely Carolyn. First I congratulate Dr. Nan chin and his colleagues. This was an 
incredibly important paper, and I think as you pointed out, one of the first to really show 
us why it is irrelevant to show us why it is relevant to identify FH at the time of an ACS. 
 
 Generally even when I work with my trainees when we talk about FH, everyone is 
thinking, "Well, we'll just put everyone on statins," and it's well appreciated. We can 
think about cascades swinging and why it's important to their offspring, but what Dr. 
Nan chin and his colleagues have certainly highlighted, is that these patients are at 
higher risks for recurrent ACS and recurrent events, and that's incredibly important as 
mentioned that tells us that maybe the routine treatment post ACS with high dose 
statins is not sufficient. 
 
 What's next is the tricky part, do we initiate PCS canine initially, do we add a zedemi 
upfront. Sort of the next step is the part that's a little bit more tricky, but I certainly see 
a potential for augmented therapy in these patients up front. 
 
Carolyn: I like the way you said tricky, and that's usually when we call for an editorial isn't it? 
 
Amat: That is correct as we will see with this article. 
 
Carolyn: I really like the title of it, "Diagnosis and Management of Petra Zygas familial 
hypercholesterolemia too little and too late." 
 
 That was very interesting, but are there any other take home messages from your end 
David? 
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David: Maybe one thing we can add ... We are currently trying to change our practice regarding 
these reasons that we have now. We have now implemented in our casualty 
department a system that's explaining strategy to identify this patient, to identify 
patient with asage. 
 
 We have a prevention team that can provide very early during hospitalization additional 
information for this patient about asage. That's one very important point is to 
encourage family testing especially for the children of the patient and also to provide 
concerning for other cardiovascular risk factors. Because we also found that half of 
these patients with asage were smokers in fact and 40% of them had hypertension. 
 
 Certainly to address the other cardio risk factor in patients with asage so certainly very 
important. At the end part of what we are doing is we are assured of the patient will an 
appropriate medical follow up in the primary care setting because it's also very 
important for management of asage and circular prevention in the primary care setting 
after discharge. 
 
Carolyn: Wow. Those are excellent points. Very practical advice on screening, management, and 
really just applying the results of what you found. Congratulations once again. 
 
 Amat I'm going to switch tracks a little bit now. Since we've got you online I really have 
to ask you a couple of things with your hat as a digital strategies editor. 
 
 Has it been two months since we first chatted even about this podcast which is part of 
the digital strategies. Let's take stock of it. How are things going? 
 
Amat: Well, so far I think excellent and frankly one of the highlights of our digital strategies is 
your podcast. It's gotten rave reviews and certainly appreciate all your enthusiasm and 
your unique take on how to do this. We've also had some excellent work with our social 
media. We have a revised website which has a lot more real estate for some novel 
offerings, and I think we certainly can't rule out traditional print media, but those 
articles that come out online. 
 
 It's been really an exciting time and thinking of novel ways to share new information in a 
modern era. 
 
Carolyn: Right. Thanks to you really Amat and I would really want to bring out one of the 
strategies that we may have not talked about so often yet, and that's the "on my mind" 
vlogs. 
 
 The reason I'm going to bring it up is because last week I was struck by the on my mind 
article by Milton Packer and it's entitled, "Heart Failure's Dark Secret. Does anyone 
really care about optimal medical therapy?" That's just awesome. Could you tell us a bit 
more about this vlog. 
 
Amat: I think you hit the nail on the head there it certainly an edgy and controversial title, and 
if you think about it that's the purpose of this in most of our academic writing. It's a little 
  
 
 
 
 Page 6 of 6 
 
bit stiff in following certain para dines, and more formal para view. The purpose here for 
the on my mind was literally that for someone who is a thought leader to free associate 
various ideas they have that would be controversial or edgy or may not be accepted 
down the main stream. 
 
 That's a bit on purpose because we hope to create a dialog around that. If you look on 
our webpage, there's actually a place where people can add comments or start a dialog 
saying whether they agree or disagree, or begin an important conversation around 
these edgy topics. 
 
Carolyn: I think that's the really cool part when we can actually start interacting with our readers 
and listeners online that way. 
 
 Thank you to my wonderful guests and thank you listeners for listening this week. Don't 
forget to tune in next week for more highlights and features. 
 
 
